Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

BANDUNG, INDONESIA, Oct 2, 2022 – (ACN Newswire) – PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23. Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23. Indonesian State-Owned Enterprises (SOEs) Minister Erick Thohir has said, "In line with the theme of the Indonesian G20 Presidency, "Recover Together, Recover Stronger", it is important … Continue reading Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

SINGAPORE, Sep 30, 2022 – (ACN Newswire) – Mainboard-listed Q&M Dental Group (Singapore) Limited [SGX: QC7] announced on 29 September 2022 the award of 2,014,245 shares to 7 promising next-generation dentists as part of the Q&M Performance Share Plan (PSP) 2018, as well as the proposed placement of an additional 4,985,755 treasury shares, totalling S$1.75 million, through placement to the same dentists.These 7 Key Dentists are the recipients of awards under the PSP 2018 by Q&M in its announcement dated 29 September 2022. These Key Dentists have also expressed their interest to subscribe for further shares as an expression of … Continue reading Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 (Osemitamab), a humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, in combination with Capecitabine and Oxaliplatin (CAPOX) as a first line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer was presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2022. In first line treatment of advanced or … Continue reading Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

Avance Clinical Wins International Health Award for Biotech CRO Services

SYDNEY, AU, Sep 28, 2022 – (ACN Newswire) – Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards – International Health category. The award recognises excellence in clinical services exports. Avance Clinical CEO Yvonne Lungershausen The Premier of South Australia Peter Malinauskas, and Minister for Trade and Investment Nick Champion, presented the Premier's Export Awards to Avance Clinical CEO Yvonne Lungershausen at the awards industry event today. This follows Avance Clinical's selection as finalist for the Informa Pharma Intelligence Awards 2022 Best Contract Research Organization in APAC. Avance Clinical, which is … Continue reading Avance Clinical Wins International Health Award for Biotech CRO Services

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sep 23, 2022 – (ACN Newswire) – AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.AIM Vaccine plans to offer an aggregate of 9,714,000 H shares (the "Offer Shares") under the Global Offering (subject to the Over-allotment Option), comprising an international offering (the "International Offering") of 8,742,400 H shares … Continue reading AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Malaysian Genomics Grows Presence in Thailand

PETALING JAYA, Malaysia, Sep 23, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a series of collaborations to grow its customer base in Thailand as well as exploring opportunities for research and development (R&D) of new products and services. Ms. Songsuda Panich, Founder of Marine Group; Encik Sasha Nordin, Chief Executive Officer of Malaysian Genomics; Mr. Choy Hong Yang, Director of Salus Holdings [L-R] Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin The Group signed a supply and collaboration agreement with Acquest Healthcare … Continue reading Malaysian Genomics Grows Presence in Thailand

Agilis Robotics Targeting its Pre-B Round Fund-raising to be Completed by 2022

HONG KONG, Sep 22, 2022 – (ACN Newswire) – Agilis Robotics Limited ("Agilis Robotics" or the "Company"), the creator of the first surgical robotic instruments in Hong Kong to target endoscopic submucosal dissection (ESD) and en bloc resection of bladder tumour (ERBT) procedures, has announced its fund-raising status, as well as its latest technological achievements.Agilis Robotics' A Round fund-raising has been completed in 2022, with the Pre-B Round, which involves fund raising for respective applications with the Food and Drug Administration (FDA) and National Medical Products Administration (NMPA) set to commence. Such efforts will go towards improving the marketisation efficiency … Continue reading Agilis Robotics Targeting its Pre-B Round Fund-raising to be Completed by 2022

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

PETALING JAYA, Malaysia, Sep 21, 2022 – (ACN Newswire) – Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines. Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min Under the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well … Continue reading Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

Novotech Presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

SYDNEY, AU, Sep 15, 2022 – (ACN Newswire) – Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference. Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific. The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC. In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW. Blood cancers (ALL, NHL, DLBCL, lymphomas), … Continue reading Novotech Presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

Indonesia’s Bio Farma ready to produce ‘IndoVac’ Covid-19 vaccines

BANDUNG, INDONESIA, Sep 12, 2022 – (ACN Newswire) – PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, its Covid-19 vaccines brand, including primary series vaccines, booster vaccines and vaccines for children, in development since November 2021. IndoVac Covid-19 vaccine in production at PT Bio Farma's facilities near Bandung, Indonesia (Image: PT Bio Farma) Honesti Baasyir, President Director of Bio Farma, said the company collaborated with Baylor College of Medicine, a private, independent health sciences centre in Houston, Texas to develop IndoVac, a recombinant protein subunit vaccine produced from yeast.According … Continue reading Indonesia’s Bio Farma ready to produce ‘IndoVac’ Covid-19 vaccines